Literature DB >> 22431853

Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.

Beverlie Baquir1, Sandrine Lemaire, Françoise Van Bambeke, Paul M Tulkens, Lin Lin, Brad Spellberg.   

Abstract

Intact phagocytic effector function is fundamental to host defense against microbial pathogens. Concern has been raised regarding the potential that accumulation of certain agents, including cationic amphiphilic antibiotics, within macrophages could cause a mixed-lipid storage disorder, resulting in macrophage dysfunction in recipients. The ability of 2 macrophage cell lines (HL-60; RAW 264.7) to kill archetypal Gram-positive (Staphylococcus aureus), Gram-negative (Acinetobacter baumannii), and fungal (Candida albicans) pathogens was tested following exposure of the macrophages to the lipoglycopeptide antibiotic oritavancin. Oritavancin did not affect killing of C. albicans but markedly enhanced killing of S. aureus by both macrophages. Oritavancin modestly reduced killing of A. baumannii by HL-60 cells but not by RAW 264.7 cells. Thus, macrophage killing of microbes remains intact despite substantial intracellular accumulation with a lipoglycopeptide antibiotic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431853      PMCID: PMC3307583          DOI: 10.1093/cid/cir921

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Role of reactive oxygen metabolites in murine peritoneal macrophage phagocytosis and phagocytic killing.

Authors:  S Takao; E H Smith; D Wang; C K Chan; G B Bulkley; A S Klein
Journal:  Am J Physiol       Date:  1996-10

2.  The immune response to staphylococcal antigens in mice depleted of macrophages by Cl2MDP-liposomes.

Authors:  W Rudnicka; M Wieckowska; N van Rooijen; B Rózalska
Journal:  Zentralbl Bakteriol       Date:  1997-11

3.  A phagocytic cell line markedly improves survival of infected neutropenic mice.

Authors:  Brad J Spellberg; Mary Collins; Samuel W French; John E Edwards; Yue Fu; Ashraf S Ibrahim
Journal:  J Leukoc Biol       Date:  2005-04-27       Impact factor: 4.962

4.  Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation.

Authors:  Françoise Van Bambeke; Jennifer Saffran; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.

Authors:  Brad J Spellberg; Mary Collins; Valentina Avanesian; Mayela Gomez; John E Edwards; Christopher Cogle; David Applebaum; Yue Fu; Ashraf S Ibrahim
Journal:  J Leukoc Biol       Date:  2006-12-08       Impact factor: 4.962

6.  Modification of neutrophil oxidant production with diphenyleneiodonium and its effect on bacterial killing.

Authors:  M B Hampton; C C Winterbourn
Journal:  Free Radic Biol Med       Date:  1995-04       Impact factor: 7.376

7.  Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis.

Authors:  Q Qian; M A Jutila; N Van Rooijen; J E Cutler
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

8.  Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.

Authors:  Sujata M Bhavnani; Julie A Passarell; Joel S Owen; Jeffrey S Loutit; Steven B Porter; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Selective eicosanoid formation during HL-60 macrophage differentiation. Regulation of thromboxane synthase.

Authors:  R Nüsing; M Goerig; A J Habenicht; V Ullrich
Journal:  Eur J Biochem       Date:  1993-03-01

10.  Common methodology is inadequate for studies on the microbicidal activity of neutrophils.

Authors:  Eva Decleva; Renzo Menegazzi; Sara Busetto; Pierluigi Patriarca; Pietro Dri
Journal:  J Leukoc Biol       Date:  2005-10-21       Impact factor: 4.962

View more
  12 in total

1.  Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Authors:  Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

2.  Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Samantha Rosenthal; Arnold G Decano; Aiman Bandali; Denise Lai; Gregory E Malat; Tiffany E Bias
Journal:  P T       Date:  2018-03

3.  Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.

Authors:  Travis B Nielsen; Paul Pantapalangkoor; Brian M Luna; Kevin W Bruhn; Jun Yan; Ken Dekitani; Sarah Hsieh; Brandon Yeshoua; Bryan Pascual; Evgeny Vinogradov; Kristine M Hujer; T Nicholas Domitrovic; Robert A Bonomo; Thomas A Russo; Magda Lesczcyniecka; Thomas Schneider; Brad Spellberg
Journal:  J Infect Dis       Date:  2017-08-15       Impact factor: 5.226

Review 4.  Oritavancin for acute bacterial skin and skin structure infections.

Authors:  Julia A Messina; Vance G Fowler; G Ralph Corey
Journal:  Expert Opin Pharmacother       Date:  2015-03-24       Impact factor: 3.889

5.  Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells.

Authors:  Laetitia G Garcia; Sandrine Lemaire; Barbara C Kahl; Karsten Becker; Richard A Proctor; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

6.  Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Authors:  Dario Lehoux; Valerie Ostiguy; Cordelia Cadieux; Mireille Malouin; Odette Belanger; Adel Rafai Far; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

7.  Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.

Authors:  Tatsuro Hirayama; Taiga Miyazaki; Yuka Yamagishi; Hiroshige Mikamo; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue; Yoshitsugu Higashi; Yoshihiro Yamamoto; Muneyoshi Kimura; Hideki Araoka; Shuichi Taniguchi; Yuichi Fukuda; Yumi Matsuo; Akiko Furutani; Kohei Yamashita; Takahiro Takazono; Tomomi Saijo; Shintaro Shimamura; Kazuko Yamamoto; Yoshifumi Imamura; Koichi Izumikawa; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 8.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

9.  Monoclonal Antibody Therapy against Acinetobacter baumannii.

Authors:  Travis B Nielsen; Jun Yan; Matthew Slarve; Peggy Lu; Rachel Li; Juan Ruiz; Bosul Lee; Elizabeth Burk; Yuli Talyansky; Peter Oelschlaeger; Kyle Hurth; William Win; Brian M Luna; Robert A Bonomo; Brad Spellberg
Journal:  Infect Immun       Date:  2021-07-26       Impact factor: 3.441

10.  Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Beverlie Baquir; Andrew Tomaras; Justin I Montgomery; Usa Reilly; Elsa G Barbacci; Kristine Hujer; Robert A Bonomo; Lucia Fernandez; Robert E W Hancock; Mark D Adams; Samuel W French; Virgil S Buslon; Brad Spellberg
Journal:  MBio       Date:  2012-10-02       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.